These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 31291219)

  • 61. Evaluation of the clinical efficacy of asenapine in schizophrenia.
    Minassian A; Young JW
    Expert Opin Pharmacother; 2010 Aug; 11(12):2107-15. PubMed ID: 20642375
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effects of asenapine in bipolar I patients meeting proxy criteria for moderate-to-severe mixed major depressive episodes: a post hoc analysis.
    Berk M; Tiller JW; Zhao J; Yatham LN; Malhi GS; Weiller E
    J Clin Psychiatry; 2015 Jun; 76(6):728-34. PubMed ID: 25612216
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Antipsychotic medications for bipolar I disorders. New atypical neuroleptic drug asenapine approved].
    Juckel G
    Nervenarzt; 2012 Mar; 83(3):384-6. PubMed ID: 22048568
    [No Abstract]   [Full Text] [Related]  

  • 64. Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia.
    Frånberg O; Wiker C; Marcus MM; Konradsson A; Jardemark K; Schilström B; Shahid M; Wong EH; Svensson TH
    Psychopharmacology (Berl); 2008 Feb; 196(3):417-29. PubMed ID: 17940749
    [TBL] [Abstract][Full Text] [Related]  

  • 65. New drug information. Saphris.
    Physician Assistants Prescribing Reference
    JAAPA; 2010 Mar; 23(3):16. PubMed ID: 20232719
    [No Abstract]   [Full Text] [Related]  

  • 66. Update on newer antipsychotic drugs.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2011 Apr; 49(4):13-5. PubMed ID: 21446639
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Development and Optimization of Asenapine Sublingual Film Using QbD Approach.
    Dalal R; Shah J; Gorain B; Choudhury H; Jacob S; Mehta TA; Shah H; Nair AB
    AAPS PharmSciTech; 2021 Oct; 22(7):244. PubMed ID: 34608546
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Atypical antipsychotics: the two new arrivals.
    Roman MW
    Issues Ment Health Nurs; 2011; 32(1):85-6. PubMed ID: 21208056
    [No Abstract]   [Full Text] [Related]  

  • 69. Asenapine-Induced Acute Dystonia in an Adolescent Male.
    Bhuyan D; Ghosh S; Bhattacharya A; Praharaj SK
    J Child Adolesc Psychopharmacol; 2016 Dec; 26(10):955-956. PubMed ID: 27154343
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Meta-analyses of the efficacy of asenapine for acute schizophrenia: comparisons with placebo and other antipsychotics.
    Szegedi A; Verweij P; van Duijnhoven W; Mackle M; Cazorla P; Fennema H
    J Clin Psychiatry; 2012 Dec; 73(12):1533-40. PubMed ID: 23290326
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control.
    Landbloom R; Mackle M; Wu X; Kelly L; Snow-Adami L; McIntyre RS; Mathews M; Hundt C
    CNS Spectr; 2017 Aug; 22(4):333-341. PubMed ID: 27821210
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The effects of the atypical antipsychotic asenapine in a strain-specific battery of tests for mania-like behaviors.
    Ene HM; Kara NZ; Einat H
    Behav Pharmacol; 2015 Jun; 26(4):331-7. PubMed ID: 25590966
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A single-dose, randomized, double-blind, placebo-controlled trial of sublingual asenapine for acute agitation.
    Pratts M; Citrome L; Grant W; Leso L; Opler LA
    Acta Psychiatr Scand; 2014 Jul; 130(1):61-8. PubMed ID: 24606117
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Asenapine: a clinical overview.
    Potkin SG
    J Clin Psychiatry; 2011; 72 Suppl 1():14-8. PubMed ID: 22217438
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Asenapine pharmacokinetics and tolerability in a pediatric population.
    Dogterom P; Riesenberg R; de Greef R; Dennie J; Johnson M; Pilla Reddy V; Miltenburg AM; Findling RL; Jakate A; Carrothers TJ; Troyer MD
    Drug Des Devel Ther; 2018; 12():2677-2693. PubMed ID: 30214156
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Asenapine effects in animal models of psychosis and cognitive function.
    Marston HM; Young JW; Martin FD; Serpa KA; Moore CL; Wong EH; Gold L; Meltzer LT; Azar MR; Geyer MA; Shahid M
    Psychopharmacology (Berl); 2009 Nov; 206(4):699-714. PubMed ID: 19462162
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The geriatric mania asenapine study (GeMS).
    Barak Y; Finkelstein I; Pridan S
    Arch Gerontol Geriatr; 2016; 64():111-4. PubMed ID: 26952385
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Asenapine: an atypical antipsychotic with atypical formulations.
    Musselman M; Faden J; Citrome L
    Ther Adv Psychopharmacol; 2021; 11():20451253211035269. PubMed ID: 34540197
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Asenapine Transdermal Patch for the Management of Schizophrenia.
    Zhou M; Derakhshanian S; Rath A; Bertrand S; DeGraw C; Barlow R; Menard A; Kaye AM; Hasoon J; Cornett EM; Kaye AD; Viswanath O; Urits I
    Psychopharmacol Bull; 2020 Sep; 50(4):60-82. PubMed ID: 33012873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.